21 research outputs found
‘WA 64’ Apple
‘WA 64’ (‘Honeycrisp’ × ‘Cripps Pink’) is a new apple selection from the Washington State University apple breeding program with commercial potential based on its exceptional eating quality, attractive appearance, and storage potential. It is a medium-sized, attractive bicolored apple with a red/pink blush over a green/yellow background. It has outstanding eating quality, being firm, crisp, and tasty. Fruit matures in ‘Golden Delicious’ season, typically mid-September in Wenatchee, WA, USA. It retains fruit quality, particularly firmness, after several months in refrigerated storage. It is suited to the fresh market with the potential to be a commercial cultivar suited for long-term storage. Slow browning flesh is a bonus for this selection
Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment-Related Adverse Events From the CheckMate 040 Study
Background. CheckMate 040 assessed the efficacy and safety
of nivolumab in patients with advanced hepatocellular carcinoma (HCC). Understanding the safety profile of nivolumab is
needed to support the management of treatment-related
adverse events (TRAEs). This analysis assessed the safety
of nivolumab monotherapy in the phase I/II, open-label
CheckMate 040 study.
Materials and Methods. Select TRAEs (sTRAEs; TRAEs with
potential immunologic etiology requiring more frequent
monitoring) occurring between first dose and 30 days after
last dose were analyzed in patients in the dose-escalation
and -expansion phases. Time to onset (TTO), time to resolution (TTR), and recurrence of sTRAEs were assessed, and
the outcome of treatment with immune-modulating medication (IMM) was evaluated.
Results. The analysis included 262 patients. The most common sTRAE was skin (35.5%), followed by gastrointestinal
(14.5%) and hepatic (14.1%) events; the majority were grade
1/2, with 10.7% of patients experiencing grade 3/4 events.
One patient had grade 5 pneumonitis. Median (range) TTO
ranged from 3.6 (0.1–59.9) weeks for skin sTRAEs to 47.6
(47.1–48.0) weeks for renal sTRAEs. Overall, 68% of sTRAEs
resolved, with median (range) TTR ranging from 3.7
(0.1–123.3+) weeks for gastrointestinal sTRAEs to 28.4
(0.1–79.1) weeks for endocrine sTRAEs. Most gastrointestinal
and all hepatic events resolved with treatment in accordance
with established toxicity management algorithms. In
57 patients (40%), sTRAEs were managed with IMM.
Reoccurrence of sTRAEs was uncommon following rechallenge
with nivolumab.
Conclusion. Nivolumab demonstrated a manageable safety
profile in this analysis of patients with advanced HCC. A
majority of sTRAEs resolved with treatment